{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:52:20Z","timestamp":1791240740769,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Nutr Rep"],"DOI":"10.1007\/s13668-026-00801-0","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:21:00Z","timestamp":1791177660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Role of Body Composition on Drug Tolerance in Cancer Therapy: A Structured Narrative Review"],"prefix":"10.1007","volume":"15","author":[{"given":"Susana","family":"Castro-Luaces","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"S\u00e1nchez-Sobrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Alfons\u00edn-Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Susana","family":"Fortes-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"V\u00e1zquez-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Barca-Diez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed Mart\u00ednez-L\u00f3pez","family":"De Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natividad","family":"Lago-Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"801_CR1","unstructured":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica (SEOM). Las cifras del c\u00e1ncer en Espa\u00f1a\u2009\u2013\u20092024. Madrid: SEOM. 2024. Available from: https:\/\/www.seom.org\/images\/LAS_CIFRAS_2024.pdf"},{"key":"801_CR2","unstructured":"World Health Organization (WHO). Global cancer burden growing amidst mounting need for services. Geneva: WHO. 2024. Available from: https:\/\/www.who.int\/es\/news\/item\/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services"},{"issue":"9","key":"801_CR3","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1093\/annonc\/mdx271","volume":"28","author":"F Bozzetti","year":"2017","unstructured":"Bozzetti F. Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy. Ann Oncol. 2017;28(9):2107\u201318. https:\/\/doi.org\/10.1093\/annonc\/mdx271.","journal-title":"Ann Oncol"},{"key":"801_CR4","unstructured":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica (SEOM). Toxicidad de los tratamientos oncol\u00f3gicos. Madrid: SEOM. 2019. Available from: https:\/\/seom.org\/guia-actualizada-de-tratamientos\/toxicidad-de-los-tratamientos-oncologicos"},{"issue":"2","key":"801_CR5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1345\/aph.1A134","volume":"36","author":"H van der Sijs","year":"2002","unstructured":"van der Sijs H, Guchelaar HJ. Formulas for calculating body surface area. Ann Pharmacother. 2002;36(2):345\u20136. https:\/\/doi.org\/10.1345\/aph.1A134.","journal-title":"Ann Pharmacother"},{"issue":"7","key":"801_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","volume":"9","author":"CMM Prado","year":"2008","unstructured":"Prado CMM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(08)70153-0.","journal-title":"Lancet Oncol"},{"issue":"12","key":"801_CR7","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","volume":"31","author":"L Martin","year":"2013","unstructured":"Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539\u201347. https:\/\/doi.org\/10.1200\/JCO.2012.45.2722.","journal-title":"J Clin Oncol"},{"issue":"2","key":"801_CR8","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/jcsm.12525","volume":"11","author":"CM Prado","year":"2020","unstructured":"Prado CM, Purcell SA, Laviano A. Nutrition interventions to treat low muscle mass in cancer. J Cachexia Sarcopenia Muscle. 2020;11(2):366\u201380. https:\/\/doi.org\/10.1002\/jcsm.12525.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"801_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruy\u00e8re O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16\u201331. https:\/\/doi.org\/10.1093\/ageing\/afy169.","journal-title":"Age Ageing"},{"issue":"5","key":"801_CR10","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1139\/H08-075","volume":"33","author":"M Mourtzakis","year":"2008","unstructured":"Mourtzakis M, Prado CMM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33(5):997\u20131006. https:\/\/doi.org\/10.1139\/H08-075.","journal-title":"Appl Physiol Nutr Metab"},{"issue":"Suppl 3","key":"801_CR11","first-page":"51","volume":"21","author":"R Burgos Pel\u00e1ez","year":"2006","unstructured":"Burgos Pel\u00e1ez R. Global therapeutic approach to sarcopenia. Nutr Hosp. 2006;21(Suppl 3):51\u201360.","journal-title":"Nutr Hosp"},{"issue":"2","key":"801_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1017\/S0029665118000046","volume":"77","author":"LE Daly","year":"2018","unstructured":"Daly LE, Prado CM, Ryan AM. A window beneath the skin: how computed tomography assessment of body composition can assist in the identification of hidden wasting conditions in oncology that profoundly impact outcomes. Proc Nutr Soc. 2018;77(2):135\u201351. https:\/\/doi.org\/10.1017\/S0029665118000046.","journal-title":"Proc Nutr Soc"},{"issue":"4","key":"801_CR13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/SPC.0000000000000450","volume":"13","author":"SM Chowdhry","year":"2019","unstructured":"Chowdhry SM, Chowdhry VK. Cancer cachexia and treatment toxicity. Curr Opin Support Palliat Care. 2019;13(4):292\u20137. https:\/\/doi.org\/10.1097\/SPC.0000000000000450.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"10","key":"801_CR14","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.endinu.2020.03.004","volume":"67","author":"A Ciudin","year":"2020","unstructured":"Ciudin A, Sim\u00f3-Servat A, Palmas F, Barahona MJ. Sarcopenic obesity: a new challenge in the clinical practice. Endocrinol Diabetes Nutr. 2020;67(10):672\u201381. https:\/\/doi.org\/10.1016\/j.endinu.2020.03.004.","journal-title":"Endocrinol Diabetes Nutr"},{"issue":"Suppl 2","key":"801_CR15","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1093\/annonc\/mdx810","volume":"29","author":"VE Baracos","year":"2018","unstructured":"Baracos VE, Arribas L. Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy. Ann Oncol. 2018;29(Suppl 2):ii1\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdx810.","journal-title":"Ann Oncol"},{"issue":"2","key":"801_CR16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1152\/jappl.2000.89.2.465","volume":"89","author":"I Janssen","year":"2000","unstructured":"Janssen I, Heymsfield SB, Baumgartner RN, Ross R. Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol. 2000;89(2):465\u201371. https:\/\/doi.org\/10.1152\/jappl.2000.89.2.465.","journal-title":"J Appl Physiol"},{"issue":"5","key":"801_CR17","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1016\/j.clnu.2020.10.048","volume":"40","author":"O Di Vincenzo","year":"2021","unstructured":"Di Vincenzo O, Marra M, Di Gregorio A, Pasanisi F, Scalfi L. Bioelectrical impedance analysis (BIA)-derived phase angle in sarcopenia: a systematic review. Clin Nutr. 2021;40(5):3052\u201361. https:\/\/doi.org\/10.1016\/j.clnu.2020.10.048.","journal-title":"Clin Nutr"},{"issue":"3","key":"801_CR18","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1590\/S0004-2803202000000-52","volume":"57","author":"APN Barr\u00e8re","year":"2020","unstructured":"Barr\u00e8re APN, Piovacari SMF, Us\u00f3n Junior PLS, Gansl RC, Pereira AZ, Hamerschlak N. Body composition impact on survival and toxicity of treatment in pancreatic cancer: cross-sectional pilot study. Arq Gastroenterol. 2020;57(3):278\u201382. https:\/\/doi.org\/10.1590\/S0004-2803202000000-52.","journal-title":"Arq Gastroenterol"},{"issue":"8","key":"801_CR19","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1016\/j.clnu.2021.06.026","volume":"40","author":"S Youn","year":"2021","unstructured":"Youn S, Chen A, Ha V, Chambers C, Eurich DT, McCall M, et al. An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel. Clin Nutr. 2021;40(8):4888\u201392. https:\/\/doi.org\/10.1016\/j.clnu.2021.06.026.","journal-title":"Clin Nutr"},{"issue":"4","key":"801_CR20","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/jjco\/hyaa247","volume":"51","author":"T Takeda","year":"2021","unstructured":"Takeda T, Sasaki T, Mie T, Furukawa T, Yamada Y, Kasuga A, et al. The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer. Jpn J Clin Oncol. 2021;51(4):604\u201311. https:\/\/doi.org\/10.1093\/jjco\/hyaa247.","journal-title":"Jpn J Clin Oncol"},{"issue":"7","key":"801_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00520-023-07890-5","volume":"31","author":"MK Jang","year":"2023","unstructured":"Jang MK, Park S, Park C, Doorenbos A, Go J, Kim S. Hematologic toxicities, sarcopenia, and body composition change in breast cancer patients undergoing neoadjuvant chemotherapy. Support Care Cancer. 2023;31(7):419. https:\/\/doi.org\/10.1007\/s00520-023-07890-5.","journal-title":"Support Care Cancer"},{"issue":"9","key":"801_CR22","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1007\/s00520-019-05279-x","volume":"28","author":"A Ueno","year":"2020","unstructured":"Ueno A, Yamaguchi K, Sudo M, Imai S. Sarcopenia as a risk factor of severe laboratory adverse events in breast cancer patients receiving perioperative epirubicin plus cyclophosphamide therapy. Support Care Cancer. 2020;28(9):4249\u201354. https:\/\/doi.org\/10.1007\/s00520-019-05279-x.","journal-title":"Support Care Cancer"},{"issue":"1","key":"801_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10549-021-06358-6","volume":"190","author":"P Sheean","year":"2021","unstructured":"Sheean P, Gomez-Perez S, Joyce C, O\u2019Connor P, Bojko M, Smith A, et al. Myosteatosis at diagnosis is adversely associated with 2-year survival in women with estrogen receptor-negative metastatic breast cancer. Breast Cancer Res Treat. 2021;190(1):121\u201332. https:\/\/doi.org\/10.1007\/s10549-021-06358-6.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"801_CR24","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/jcsm.12538","volume":"11","author":"MP Chu","year":"2020","unstructured":"Chu MP, Li Y, Ghosh S, Sass S, Smylie M, Walker J, et al. Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma. J Cachexia Sarcopenia Muscle. 2020;11(3):748\u201355. https:\/\/doi.org\/10.1002\/jcsm.12538.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"801_CR25","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/jcsm.12436","volume":"10","author":"S Kurk","year":"2019","unstructured":"Kurk S, Peeters P, Stellato R, Dorresteijn B, de Jong P, Jourdan M, et al. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients. J Cachexia Sarcopenia Muscle. 2019;10(4):803\u201313. https:\/\/doi.org\/10.1002\/jcsm.12436.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"12","key":"801_CR26","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1080\/0284186X.2021.1983210","volume":"60","author":"K Bruno","year":"2021","unstructured":"Bruno K, de Sobreira da Silva A, Chaves MJ. Association of body composition with toxicity to first-line chemotherapy and three-year survival in women with ovarian adenocarcinoma. Acta Oncol. 2021;60(12):1611\u201320. https:\/\/doi.org\/10.1080\/0284186X.2021.1983210.","journal-title":"Acta Oncol"},{"issue":"11","key":"801_CR27","doi-asserted-by":"publisher","first-page":"9501","DOI":"10.3390\/curroncol30110688","volume":"30","author":"R Shah","year":"2023","unstructured":"Shah R, Polen-De C, McGree M, Fought A, Kumar A. Re-evaluating chemotherapy dosing strategies for ovarian cancer: impact of sarcopenia. Curr Oncol. 2023;30(11):9501\u201313. https:\/\/doi.org\/10.3390\/curroncol30110688.","journal-title":"Curr Oncol"},{"issue":"5","key":"801_CR28","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(10)70218-7.","journal-title":"Lancet Oncol"},{"issue":"7","key":"801_CR29","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1080\/01635581.2021.2012209","volume":"74","author":"L Flores-Cisneros","year":"2022","unstructured":"Flores-Cisneros L, Cetina-P\u00e9rez L, Galicia-Carmona T, Jimenez-Lima R, Gonz\u00e1lez-Islas D, Parra-Solano A, et al. Handgrip strength, overhydration and nutritional status as predictors of gastrointestinal toxicity in cervical cancer patients: a prospective study. Nutr Cancer. 2022;74(7):2444\u201350. https:\/\/doi.org\/10.1080\/01635581.2021.2012209.","journal-title":"Nutr Cancer"},{"issue":"2","key":"801_CR30","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1007\/s00330-023-09712-y","volume":"34","author":"A Surov","year":"2024","unstructured":"Surov A, Meyer HJ, Hinnerichs M, Ferraro V, Zeremski V, Mougiakakos D, et al. CT-defined sarcopenia predicts treatment response in primary central nervous system lymphomas. Eur Radiol. 2024;34(2):790\u20136. https:\/\/doi.org\/10.1007\/s00330-023-09712-y.","journal-title":"Eur Radiol"},{"issue":"2","key":"801_CR31","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3390\/curroncol28020126","volume":"28","author":"J Guo","year":"2021","unstructured":"Guo J, Cai P, Li P, Cao C, Zhou J, Dong L, et al. Body composition as a predictor of toxicity and prognosis in patients with diffuse large B-cell lymphoma receiving R-CHOP immunochemotherapy. Curr Oncol. 2021;28(2):1325\u201337. https:\/\/doi.org\/10.3390\/curroncol28020126.","journal-title":"Curr Oncol"},{"issue":"3","key":"801_CR32","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1002\/jcsm.12967","volume":"13","author":"C de Jong","year":"2022","unstructured":"de Jong C, Chargi N, Herder GJM, van Haarlem SWA, van der Meer F, van Lindert ASR, et al. The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients. J Cachexia Sarcopenia Muscle. 2022;13(3):1554\u201364. https:\/\/doi.org\/10.1002\/jcsm.12967.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"801_CR33","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejca.2019.11.003","volume":"124","author":"L Hirsch","year":"2020","unstructured":"Hirsch L, Bellesoeur A, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Kirchgesner J, et al. The impact of body composition parameters on severe toxicity of nivolumab. Eur J Cancer. 2020;124:170\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2019.11.003.","journal-title":"Eur J Cancer"},{"issue":"12","key":"801_CR34","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1089\/thy.2018.0784","volume":"29","author":"O Huillard","year":"2019","unstructured":"Huillard O, Jouinot A, Tlemsani C, Brose MS, Arrondeau J, Meinhardt G, et al. Body composition in patients with radioactive iodine-refractory, advanced differentiated thyroid cancer treated with sorafenib or placebo: a retrospective analysis of the phase III DECISION trial. Thyroid. 2019;29(12):1820\u20137. https:\/\/doi.org\/10.1089\/thy.2018.0784.","journal-title":"Thyroid"},{"issue":"2","key":"801_CR35","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.21873\/anticanres.14060","volume":"40","author":"CH Huang","year":"2020","unstructured":"Huang CH, Lue KH, Hsieh TC, Liu SH, Wang TF, Peng TC. Association between sarcopenia and clinical outcomes in patients with esophageal cancer under neoadjuvant therapy. Anticancer Res. 2020;40(2):1175\u201381. https:\/\/doi.org\/10.21873\/anticanres.14060.","journal-title":"Anticancer Res"},{"key":"801_CR36","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejca.2021.10.010","volume":"160","author":"N Chargi","year":"2022","unstructured":"Chargi N, Molenaar-Kuijsten L, Huiskamp LFJ, Devriese LA, de Bree R, Huitema ADR. The association of cisplatin pharmacokinetics and skeletal muscle mass in patients with head and neck cancer: the prospective PLATISMA study. Eur J Cancer. 2022;160:92\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2021.10.010.","journal-title":"Eur J Cancer"},{"key":"801_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.oraloncology.2017.05.012","volume":"71","author":"AW Wendrich","year":"2017","unstructured":"Wendrich AW, Swartz JE, Bril SI, Wegner I, de Graeff A, Smid EJ, et al. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. Oral Oncol. 2017;71:26\u201333. https:\/\/doi.org\/10.1016\/j.oraloncology.2017.05.012.","journal-title":"Oral Oncol"},{"issue":"7","key":"801_CR38","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1007\/s00405-021-07229-y","volume":"279","author":"N Chargi","year":"2022","unstructured":"Chargi N, Bashiri F, Wendrich AW, Smid EJ, de Jong PA, Huitema ADR, et al. Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer. Eur Arch Otorhinolaryngol. 2022;279(7):3685\u201394. https:\/\/doi.org\/10.1007\/s00405-021-07229-y.","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"801_CR39","unstructured":"National Cancer Institute. CTEP trial development and conduct. Bethesda: National Cancer Institute. 2025. Available from: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/trial-development"},{"issue":"5\u20136","key":"801_CR40","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10585-018-9893-y","volume":"35","author":"N Turner","year":"2018","unstructured":"Turner N, Ware O, Bosenberg M. Genetics of metastasis: melanoma and other cancers. Clin Exp Metastasis. 2018;35(5\u20136):379\u201391. https:\/\/doi.org\/10.1007\/s10585-018-9893-y.","journal-title":"Clin Exp Metastasis"},{"issue":"9980","key":"801_CR41","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(14)62004-3","volume":"385","author":"LHJ Simkens","year":"2015","unstructured":"Simkens LHJ, van Tinteren H, May A, ten Tije AJ, Creemers GJM, Loosveld OJL, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015;385(9980):1843\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(14)62004-3.","journal-title":"Lancet"},{"issue":"5","key":"801_CR42","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","volume":"31","author":"JD Cox","year":"1995","unstructured":"Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341\u20136. https:\/\/doi.org\/10.1016\/0360-3016(95)00060-C.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"801_CR43","unstructured":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica (SEOM). Tumores de cabeza y cuello: Tiroides. Madrid: SEOM. 2019. Available from: https:\/\/seom.org\/info-sobre-el-cancer\/tiroides?start=1"},{"issue":"9940","key":"801_CR44","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(14)60421-9.","journal-title":"Lancet"},{"issue":"3","key":"801_CR45","first-page":"178","volume":"7","author":"J Larrea","year":"1992","unstructured":"Larrea J, Vega S, Mart\u00ednez T, Torrent JM, Vega V, N\u00fa\u00f1ez V. [The nutritional status and immunological situation of cancer patients]. Nutr Hosp. 1992;7(3):178\u201384.","journal-title":"Nutr Hosp"},{"key":"801_CR46","unstructured":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica (SEOM). Tumores de cabeza y cuello: O.R.L, Madrid. SEOM; 2019. Available from: https:\/\/seom.org\/info-sobre-el-cancer\/orl?start=1"},{"issue":"11","key":"801_CR47","doi-asserted-by":"publisher","first-page":"e79603","DOI":"10.1371\/journal.pone.0079603","volume":"8","author":"K Trobec","year":"2013","unstructured":"Trobec K, Kerec Kos M, von Haehling S, Springer J, Anker SD, Lainscak M. Pharmacokinetics of drugs in cachectic patients: a systematic review. PLoS ONE. 2013;8(11):e79603. https:\/\/doi.org\/10.1371\/journal.pone.0079603.","journal-title":"PLoS ONE"},{"issue":"23","key":"801_CR48","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1200\/JCO-24-02754","volume":"43","author":"E Assenat","year":"2025","unstructured":"Assenat E, Ben Abdelghani M, Gourgou S, Perrier H, Akouz FK, Desgrippes R, et al. Impact of lean body mass-based oxaliplatin dose calculation on neurotoxicity in adjuvant treatment of stage III colon cancer: results of the phase II randomized LEANOX trial. J Clin Oncol. 2025;43(23):2616\u201327. https:\/\/doi.org\/10.1200\/JCO-24-02754.","journal-title":"J Clin Oncol"}],"container-title":["Current Nutrition Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13668-026-00801-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13668-026-00801-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13668-026-00801-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:04:12Z","timestamp":1791237852000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13668-026-00801-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["801"],"URL":"https:\/\/doi.org\/10.1007\/s13668-026-00801-0","relation":{},"ISSN":["2161-3311"],"issn-type":[{"value":"2161-3311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Institutional Review Board","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"81"}}